
( (S 
    (NP-SBJ (NNP Amgen) (NNP Inc.) )
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S 
          (NP-SBJ (PRP$ its) (JJ second-quarter) (NNS earnings) )
          (VP (VBD increased) 
            (ADVP (RBR more) (IN than) (RB tenfold) )
            (PP-DIR (TO to) 
              (NP 
                (NP 
                  (QP ($ $) (CD 3.9) (CD million) )
                  (-NONE- *U*) )
                (, ,) (CC or) 
                (NP 
                  (NP (CD 22) (NNS cents) )
                  (NP-ADV (DT a) (NN share) ))))
            (, ,) 
            (PP-PRP (JJ due) 
              (PP (TO to) 
                (NP 
                  (NP (VBN increased) (NNS sales) )
                  (PP (IN of) 
                    (NP 
                      (NP 
                        (NP (DT the) (NN company) (POS 's) )
                        (JJ new) (JJ antianemia) (NN drug) )
                      (PP (IN for) 
                        (NP (NN kidney) (NNS patients) )))))))))))
    (. .) ))
( (S 
    (NP-SBJ (DT The) 
      (ADJP (NNP Thousand) (NNP Oaks) 
        (, ,)
        (JJ Calif.-based) )
      (NN biotechnology) (NN company) )
    (VP (VBD reported) 
      (NP 
        (NP (DT a) 
          (ADJP (CD 97) (NN %) )
          (NN increase) )
        (PP-LOC (IN in) 
          (NP (NN revenue) ))
        (PP (TO to) 
          (NP 
            (QP ($ $) (CD 42.5) (CD million) )
            (-NONE- *U*) )))
      (PP (IN for) 
        (NP 
          (NP (DT the) (NN quarter) )
          (VP (VBN ended) 
            (NP-TMP (NNP Sept.) (CD 30) )))))
    (. .) ))
( (S 
    (PP-TMP (IN In) 
      (NP (DT the) (JJ year-ago) (NN period) ))
    (, ,) 
    (NP-SBJ (NNP Amgen) )
    (VP (VBD reported) 
      (NP 
        (NP (JJ net) (NN income) )
        (PP (IN of) 
          (NP 
            (NP ($ $) (CD 320,000) (-NONE- *U*) )
            (, ,) (CC or) 
            (NP 
              (NP (CD two) (NNS cents) )
              (NP-ADV (DT a) (NN share) ))))
        (, ,) 
        (PP (IN on) 
          (NP 
            (NP (NN revenue) )
            (PP (IN of) 
              (NP 
                (QP ($ $) (CD 21.5) (CD million) )
                (-NONE- *U*) ))))))
    (. .) ))
( (S 
    (PP (IN For) 
      (NP (DT the) (CD six) (NNS months) ))
    (, ,) 
    (NP-SBJ (DT the) (NN company) )
    (VP (VBD reported) 
      (NP 
        (NP (DT a) 
          (ADVP (JJR more) (IN than) (JJ sixfold) )
          (NN increase) )
        (PP-LOC (IN in) 
          (NP (NNS earnings) ))
        (PP (TO to) 
          (NP 
            (NP 
              (QP ($ $) (CD 4.7) (CD million) )
              (-NONE- *U*) )
            (, ,) (CC or) 
            (NP 
              (NP (CD 26) (NNS cents) )
              (NP-ADV (DT a) (NN share) ))))
        (, ,) 
        (PP (IN from) 
          (NP 
            (NP ($ $) (CD 625,000) (-NONE- *U*) )
            (, ,) (CC or) 
            (NP 
              (NP (CD four) (NNS cents) )
              (NP-ADV (DT a) (NN share) )))
          (ADVP-TMP 
            (NP (DT a) (NN year) )
            (RB ago) ))))
    (. .) ))
( (S 
    (NP-SBJ (NN Revenue) )
    (VP (VBD rose) 
      (NP-EXT (CD 77) (NN %) )
      (PP-DIR (TO to) 
        (NP 
          (QP ($ $) (CD 72.6) (CD million) )
          (-NONE- *U*) ))
      (, ,) 
      (PP-DIR (IN from) 
        (NP 
          (NP (JJ last) (NN year) (POS 's) )
          (QP ($ $) (CD 41) (CD million) )
          (-NONE- *U*) )))
    (. .) ))
